BAI1/ADGRB1: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of BAI1/ADGRB1. The page also collects GeneMedi's different modalities and formats products for BAI1 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the BAI1 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
Angiogenesis is controlled by a local balance between stimulators and inhibitors of new vessel growth and is suppressed under normal physiologic conditions. Angiogenesis has been shown to be essential for growth and metastasis of solid tumors. In order to obtain blood supply for their growth, tumor cells are potently angiogenic and attract new vessels as results of increased secretion of inducers and decreased production of endogenous negative regulators.? BAI1 contains at least one 'functional' p53-binding site within an intron, and its expression has been shown to be induced by wildtype p53. There are two other brain-specific angiogenesis inhibitor genes, designated BAI2 and BAI3 which along with BAI1 have similar tissue specificities and structures, however only BAI1 is transcriptionally regulated by p53. BAI1 is postulated to be a member of the secretin receptor family, an inhibitor of angiogenesis and a growth suppressor of glioblastomas [provided by RefSeq, Jul 2008]
Target ID | GM-T41036 |
Target Name | BAI1 |
Gene ID | 575,107831,362931,694367,100683150,101086453,524070,102148282 |
Gene Symbol and Synonyms | ADGRB1,B830018M07Rik,BAI1,GDAIF,mKIAA4089 |
Uniprot Accession | O14514,C0HL12 |
Uniprot Entry Name | AGRB1_HUMAN,AGRB1_RAT |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Immuno-oncology Target |
Disease | Cancer |
Gene Ensembl | ENSG00000181790 |
Target Classification | Checkpoint-Immuno Oncology, Tumor-associated antigen (TAA) |
Pre-made anti-BAI1 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-BAI1 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-BAI1 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Antibody Name | Species | Format | Classified by tag | Detail |
Anti-BAI1/ADGRB1 monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | FACS/Biofunctional Antibody, Therapeutics Target antibody | Detail |
Multi-species AGRB1/ BAI1/ ADGRB1 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine BAI1/ADGRB1 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Products Name | Species | Expression Platform | Detail |
BAI1/ADGRB1 VLP (virus-like particle) | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Products Developing |